Silvercrest Asset Management’s Castle Biosciences CSTL Stock Holding History

Silvercrest Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.11M	Sell	256,095 -12,440	-5%	-$277K	0.04%	422
2026 Q1	$6.59M	Buy	268,535 +63,533	+31%	+$2.08M	0.05%	387
2025 Q4	$7.97M	Sell	205,002 -162,886	-44%	-$5.25M	0.05%	368
2025 Q3	$8.38M	Buy	367,888 +87,929	+31%	+$1.79M	0.06%	346
2025 Q2	$5.72M	Buy	279,959 +81,157	+41%	+$1.5M	0.04%	411
2025 Q1	$3.98M	Sell	198,802 -1,148	-0.6%	-$28.4K	0.03%	444
2024 Q4	$5.33M	Sell	199,950 -1,971	-1%	-$60K	0.04%	415
2024 Q3	$5.76M	Buy	+201,921	New	+$5.14M	0.04%	361

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silvercrest Asset Management's CSTL Position: Q2 2026 in Review

Silvercrest Asset Management reduced its Castle Biosciences (CSTL) stake by 4.6% in Q2 2026, selling an estimated $277K and leaving 256,095 shares worth $6.11M. The position accounts for 0.04% of the portfolio, ranked #422.

Silvercrest Asset Management first reported a position in CSTL in Q3 2024 and has held it in 8 quarters since. The position peaked at $8.38M in Q3 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Silvercrest Asset Management held 256,095 shares of Castle Biosciences worth $6.11M as of Q2 2026.
Silvercrest Asset Management sold 12,440 Castle Biosciences shares in Q2 2026, an estimated $277K.
Castle Biosciences made up 0.04% of Silvercrest Asset Management's portfolio in Q2 2026, its #422 holding.
Silvercrest Asset Management first reported a position in Castle Biosciences in Q3 2024 and has held it in 8 quarters since.
Silvercrest Asset Management's Castle Biosciences position peaked at $8.38M in Q3 2025.
177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.